These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

50 related items for PubMed ID: 8845302

  • 1. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene.
    Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS, Bigner DD.
    Cell Growth Differ; 1995 Oct; 6(10):1251-9. PubMed ID: 8845302
    [Abstract] [Full Text] [Related]

  • 2. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
    Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME.
    Cancer Res; 2000 Jun 01; 60(11):3081-7. PubMed ID: 10850460
    [Abstract] [Full Text] [Related]

  • 3. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor.
    Moscatello DK, Montgomery RB, Sundareshan P, McDanel H, Wong MY, Wong AJ.
    Oncogene; 1996 Jul 04; 13(1):85-96. PubMed ID: 8700557
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
    Lammering G, Hewit TH, Holmes M, Valerie K, Hawkins W, Lin PS, Mikkelsen RB, Schmidt-Ullrich RK.
    Clin Cancer Res; 2004 Oct 01; 10(19):6732-43. PubMed ID: 15475464
    [Abstract] [Full Text] [Related]

  • 5. Mathematical model for the effects of epidermal growth factor receptor trafficking dynamics on fibroblast proliferation responses.
    Starbuck C, Lauffenburger DA.
    Biotechnol Prog; 1992 Oct 01; 8(2):132-43. PubMed ID: 1368006
    [Abstract] [Full Text] [Related]

  • 6. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.
    Lorimer IA, Wikstrand CJ, Batra SK, Bigner DD, Pastan I.
    Clin Cancer Res; 1995 Aug 01; 1(8):859-64. PubMed ID: 9816055
    [Abstract] [Full Text] [Related]

  • 7. Intracellular transactivation of the insulin-like growth factor I receptor by an epidermal growth factor receptor.
    Burgaud JL, Baserga R.
    Exp Cell Res; 1996 Mar 15; 223(2):412-9. PubMed ID: 8601418
    [Abstract] [Full Text] [Related]

  • 8. Differential heat stress stability of epidermal growth factor receptor and erbB-2 receptor tyrosine kinase activities.
    Liu SM, Carpenter G.
    J Cell Physiol; 1993 Nov 15; 157(2):237-42. PubMed ID: 7901224
    [Abstract] [Full Text] [Related]

  • 9. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 10. Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae.
    Abulrob A, Giuseppin S, Andrade MF, McDermid A, Moreno M, Stanimirovic D.
    Oncogene; 2004 Sep 09; 23(41):6967-79. PubMed ID: 15273741
    [Abstract] [Full Text] [Related]

  • 11. c-Myc is required for transformation of FDC-P1 cells by EGFRvIII.
    Rath O, Himmler A, Baum A, Sommergruber W, Beug H, Metz T.
    FEBS Lett; 2007 May 29; 581(13):2549-56. PubMed ID: 17499721
    [Abstract] [Full Text] [Related]

  • 12. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
    Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ.
    Cancer Res; 1995 Jul 15; 55(14):3140-8. PubMed ID: 7606735
    [Abstract] [Full Text] [Related]

  • 13. Ornithine decarboxylase transformation of NIH/3T3 cells is mediated by altered epidermal growth factor receptor activity.
    Moshier JA, Malecka-Panas E, Geng H, Dosescu J, Tureaud J, Skunca M, Majumdar AP.
    Cancer Res; 1995 Nov 15; 55(22):5358-65. PubMed ID: 7585601
    [Abstract] [Full Text] [Related]

  • 14. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R, Habib AA.
    Cancer Res; 2006 Jan 15; 66(2):867-74. PubMed ID: 16424019
    [Abstract] [Full Text] [Related]

  • 15. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
    Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, Bar-Eli M.
    Clin Cancer Res; 2006 Aug 01; 12(15):4671-7. PubMed ID: 16899617
    [Abstract] [Full Text] [Related]

  • 16. Retroviruses expressing different levels of the normal epidermal growth factor receptor: biological properties and new bioassay.
    Velu TJ, Beguinot L, Vass WC, Zhang K, Pastan I, Lowy DR.
    J Cell Biochem; 1989 Feb 01; 39(2):153-66. PubMed ID: 2565908
    [Abstract] [Full Text] [Related]

  • 17. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW, Murray DK, Elliott WL, Fry DW, Howard CT, Nelson JM, Roberts BJ, Vincent PW, Showalter HD, Winters RT, Denny WA.
    J Med Chem; 1998 Feb 26; 41(5):742-51. PubMed ID: 9513602
    [Abstract] [Full Text] [Related]

  • 18. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ, Huang HJ, Cavenee WK.
    Cancer Res; 2001 Jul 15; 61(14):5349-54. PubMed ID: 11454673
    [Abstract] [Full Text] [Related]

  • 19. Identification of novel peptide ligands for the cancer-specific receptor mutation EFGRvIII using a mixture-based synthetic combinatorial library.
    Denholt CL, Hansen PR, Pedersen N, Poulsen HS, Gillings N, Kjaer A.
    Biopolymers; 2009 Mar 15; 91(3):201-6. PubMed ID: 19107925
    [Abstract] [Full Text] [Related]

  • 20. Kinetics of activation of the tyrosine kinase of a deletion mutant of epidermal growth factor receptor missing the sites of self-phosphorylation.
    Sherrill JM, Kyte J.
    Biochemistry; 1999 Mar 09; 38(10):3106-11. PubMed ID: 10074364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.